We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


FAQ on the New Chapter 2.1.7 of the European Pharmacopoeia

On January 1st, 2022, the new Chapter 2.1.7, published by the European Pharmacopoeia (Ph.Eur.) and pertaining to balances used for analytical purposes, became effective. The Ph.Eur. is the legally binding reference for all pharmaceutical companies placing pharmaceutical products in the market of European member states.

Download this guide to discover the answers to these commonly asked questions about Ph.Eur. compliance:

  • What are the requirements of Chapter 2.1.7 concerning the calibration of a balance?
  • What are the requirements on repeatability and sensitivity?
  • How often should performance checks be conducted?
  • How does the CubisĀ® II laboratory balance support compliance with Chapter 2.1.7?